Citations

Clear

5 citation(s) found for "Jimeno, Antonio".

NCCN Guidelines® Insights: Head and Neck Cancers, Version 2.2025
Pfister, David G. , Spencer, Sharon A., Adkins, Douglas, Birkeland, Andrew C. , Busse, Paul M., Durm, Greg Andrew , Fakhry, Carole , Galloway, Thomas J. , Geiger, J.L. , Gillison, Maura L. , Haddad, Robert I. , Hitchcock, Ying J. , Jimeno, Antonio , Leizman, Debra S., Maghami, Ellie, Mell, Loren K. , Pinto, Harlan A. , Price, Katharine A. , Rocco, James W. , Rodriguez, Cristina P. , Sher, David J. , Wang, He , Weinstein, Gregory S., Yom, Sue S. , Zhen, Weining, Darlow, Susan, Price, Katharine, Haddad, Robert , Yom, Sue S , Colevas, Alexander Dimitrios , Cmelak, Anthony J. , Adkins, Douglas, Brizel, David M. , Caudell, Jimmy J , Glastonbury, Christine M. , Hicks, Wesley L. , Juloori, Aditya , Kase, Michael, Mittal, Bharat B. , Schwartz, David A. , Shah, Jatin P. , John, Maie A. St. , Worden, Francis P. , Bruce, Justine Y. , Montgomery, Sarah E.

Mayo Clinic

Journal of the National Comprehensive Cancer Network | February 12, 2025 | Volume: 23 | Issue: 2 | Pages: 2-11

10.6004/jnccn.2025.0007 | PMID 39938471 Get It

The NCCN Guidelines for Head and Neck Cancers address tumors arising in the oral cavity (including mucosal lip), pharynx, larynx, and paranasal sinuses, as well as occult primary cancer, salivary gland cancer, and mucosal melanoma (MM). The specific site of disease, stage, and pathologic findings guide treatment (eg, the appropriate surgical procedure, radiation targets, dose and fractionation of radiation, indications for systemic therapy). The NCCN Head and Neck Cancers Panel meets at least annually to review comments from reviewers within their institutions, examine relevant new data from publications and abstracts, and reevaluate and update their recommendations. These NCCN Guidelines Insights summarize the panel’s most recent recommendations regarding management of nasopharynx cancer and ongoing research in this area.
NCCN Guidelines® Insights: Head and Neck Cancers, Version 1.2022
Gillison, Maura L. , Maghami, Ellie, Spencer, Sharon, Pfister, David G. , Birkeland, Andrew C. , Busse, Paul M., Cmelak, Anthony J. , Eisele, David W. , Galloway, Thomas J. , Geiger, J.L. , Haddad, Robert I. , Hicks, Wesley L. , Hitchcock, Ying J. , Jimeno, Antonio , Leizman, Debra S., Mell, Loren K. , Mittal, Bharat B. , Pinto, Harlan A. , Rocco, James W. , Rodriguez, Cristina P. , Savvides, P. , Sher, David J. , Weber, Randal S. , Weinstein, Gregory S., Worden, Frank , Yom, Sue S. , Zhen, Weining, Burns, Jennifer L. , Darlow, Susan, Savvides, Panayiotis S, Haddad, Robert , Mittal, Bharat B , Yom, Sue S , Caudell, Jimmy J , Adkins, Douglas R. , Brizel, David M. , Colevas, Alexander Dimitrios , Schwartz, David A. , Shah, Jatin P. , John, Maie A. St. , Bruce, Justine Y.

Mayo Clinic

Journal of the National Comprehensive Cancer Network | March 11, 2022 | Volume: 20 | Issue: 3 | Pages: 224-234

10.6004/jnccn.2022.0016 | PMID 35276673 Get It

The NCCN Guidelines for Head and Neck Cancers address tumors arising in the oral cavity (including mucosal lip), pharynx, larynx, and paranasal sinuses. Occult primary cancer, salivary gland cancer, and mucosal melanoma (MM) are also addressed. The specific site of disease, stage, and pathologic findings guide treatment (eg, the appropriate surgical procedure, radiation targets, dose and fractionation of radiation, indications for systemic therapy). The NCCN Head and Neck Cancers Panel meets at least annually to review comments from reviewers within their institutions, examine relevant new data from publications and abstracts, and reevaluate and update their recommendations. These NCCN Guidelines Insights summarize the panel’s most recent recommendations regarding management of HPV-positive oropharynx cancer and ongoing research in this area.
Head and Neck Cancers, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology
Pfister, David G. , Spencer, Sharon, Adelstein, David J. , Brizel, David M. , Busse, Paul M., Cmelak, Anthony J. , Eisele, David W. , Fenton, Moon J. , Foote, Robert L. , Galloway, Thomas J. , Gillison, Maura L. , Haddad, Robert I. , Hicks, Wesley L. , Hitchcock, Ying J. , Jimeno, Antonio , Leizman, Debra S., Maghami, Ellie, Mell, Loren K. , Mittal, Bharat B. , Pinto, Harlan A. , Rocco, James W. , Rodriguez, Cristina P. , Weber, Randal S. , Weinstein, Gregory S., Witek, Matthew E. , Worden, Frank , Yom, Sue S. , Zhen, Weining, Burns, Jennifer L. , Darlow, Susan, Brizel, David M , Haddad, Robert , Mittal, Bharat B , Yom, Sue S , Adkins, Douglas R. , Anzai, Yoshimi , Bruce, Justine Y. , Caudell, Jimmy J , Colevas, Alexander Dimitrios , Ridge, John Andrew , Shah, Jatin P.

Mayo Clinic

Journal of the National Comprehensive Cancer Network | July 7, 2020 | Volume: 18 | Issue: 7 | Pages: 873-898

10.6004/jnccn.2020.0031 | PMID 32634781 Get It

Treatment is complex for patients with head and neck (H&N) cancers with specific site of disease, stage, and pathologic findings guiding treatment decision-making. Treatment planning for H&N cancers involves a multidisciplinary team of experts. This article describes supportive care recommendations in the NCCN Guidelines for Head and Neck Cancers, as well as the rationale supporting a new section on imaging recommendations for patients with H&N cancers. This article also describes updates to treatment recommendations for patients with very advanced H&N cancers and salivary gland tumors, specifically systemic therapy recommendations.
A phase I study to evaluate safety, tolerability, pharmacokinetics and activity of oraxol in patients (pts) with advanced malignancies.
Azad, Nilofer S. , Dy, Grace K. , Gallagher, Denise , Brennen, Caden, Cutler, David L. , Kramer, Douglas, Kwan, Rudolf, Fetterly, Gerald J., Adjei, Alex A. , Jimeno, Antonio , Wee, Wen , Lam, Elaine T. , Diamond, Jennifer R. , Opyrchal, Mateusz , Chan, Wing‐Kai

Mayo Clinic

Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: 2526-2526

10.1200/jco.2018.36.15_suppl.2526 Get It

A Phase I Study of EKB-569 in Combination with Capecitabine in Patients with Advanced Colorectal Cancer
Laheru, Dan, Croghan, Gary A., Bukowski, Ronald M., Messersmith, Wells A. , Erlichman, Charles , Pelley, Robert, Jimeno, Antonio , Donehower, Ross C. , Boni, Joseph , Abbas, Richat, Martins, Patrícia Rocha , Zacharchuk, Charles, Hidalgo, Manuel , Rudek, Michelle A.

Mayo Clinic

Clinical Cancer Research | September 2, 2008 | Volume: 14 | Issue: 17 | Pages: 5602-5609

10.1158/1078-0432.ccr-08-0433 | PMID 18765554 Get It

Abstract Purpose: To determine the maximum tolerated dose (MTD), characterize the principal toxicities, and assess the pharmacokinetics of EKB-569, an oral selective irreversible inhibitor of the epidermal growth factor receptor tyrosine kinase, in combination with capecitabine in patients with advanced colorectal cancer. Experimental Design: Patients were treated with EKB-569 daily for 21 days and capecitabine twice daily for 14 days of a 21-day cycle. The dose levels of EKB-569 (mg/day) and capecitabine (mg/m2 twice daily) assessed were 25/750, 50/750, 50/1,000 and 75/1,000. An expanded cohort was enrolled at the MTD to better study toxicity and efficacy. Samples of plasma were collected to characterize the pharmacokinetics of the agents. Treatment efficacy was assessed every other cycle. Results: A total of 37 patients, the majority of whom had prior chemotherapy, received a total of 163 cycles of treatment. Twenty patients were treated at the MTD, 50 mg EKB-569, daily and 1,000 mg/m2 capecitabine twice daily. Dose-limiting toxicities were diarrhea and rash. No patients had complete or partial responses but 48% had stable disease. The conversion of capecitabine to 5-fluorouracil was higher for the combination of EKB-569 and capecitabine (321 ± 151 ng*h/mL) than for capecitabine alone (176 ± 62 ng*hours/mL; P = 0.0037). Conclusion: In advanced colorectal cancer, 50 mg EKB-569 daily can be safely combined with 1,000 mg/m2 capecitabine twice a day. A statistically significant increase in plasma levels of 5-fluorouracil for the combination of EKB-569 and capecitabine may be due to the single-dose versus multiple-dose exposure difference, variability in exposure or a potential drug interaction.